Insmed, Inc. $INSM Stock: Eurizon Capital SGR S.p.A. Raises Stake

Eurizon Capital SGR S.p.A. boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 35.6% during the third quarter, Holdings Channel reports. The firm owned 27,457 shares of the biopharmaceutical company’s stock after purchasing an additional 7,210 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Insmed were worth $3,138,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in INSM. Pictet Asset Management Holding SA grew its position in Insmed by 44.0% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock worth $200,845,000 after purchasing an additional 537,188 shares during the period. Sei Investments Co. raised its stake in Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after buying an additional 505,624 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Insmed during the 2nd quarter valued at $139,966,000. Assenagon Asset Management S.A. lifted its holdings in shares of Insmed by 480.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock valued at $144,591,000 after buying an additional 1,048,518 shares during the period. Finally, NWI Management LP lifted its holdings in shares of Insmed by 2.6% during the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock valued at $165,809,000 after buying an additional 25,540 shares during the period.

Insmed Stock Performance

INSM opened at $122.88 on Tuesday. The company’s 50 day moving average is $110.75 and its 200 day moving average is $123.20. The company has a current ratio of 2.86, a quick ratio of 2.59 and a debt-to-equity ratio of 0.77. The company has a market cap of $26.96 billion, a price-to-earnings ratio of -43.57 and a beta of 0.83. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The business had revenue of $524.43 million for the quarter, compared to analysts’ expectations of $500.36 million. During the same period in the prior year, the company posted ($1.75) earnings per share. The firm’s quarterly revenue was up 268.4% on a year-over-year basis. On average, equities research analysts predict that Insmed, Inc. will post -1.86 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on INSM. Wolfe Research downgraded Insmed from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. Mizuho set a $154.00 price objective on Insmed in a report on Thursday, October 29th. JPMorgan Chase & Co. reduced their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, August 10th. Benchmark reissued a “buy” rating on shares of Insmed in a report on Monday, November 2nd. Finally, Wells Fargo & Company increased their target price on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $196.52.

Check Out Our Latest Report on INSM

Insider Buying and Selling at Insmed

In other news, Director David Brennan sold 25,000 shares of Insmed stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director owned 39,238 shares in the company, valued at $4,865,512. This trade represents a 38.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.10% of the stock is owned by corporate insiders.

Insmed Company Profile

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

See Also

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.